Suggested Readings

Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M).

Chounta V, Overton ET, Mills A, et al. Patient. 2021;14(6):849-862.

New York State Department of Health AIDS Institute Clinical Guidelines. In: Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults.

McGowan JP, Fine SM, et al. Baltimore, MD: Johns Hopkins University; 2021.

Lenacapavir: a first-in-class HIV-1 capsid inhibitor.

Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Curr Opin HIV AIDS. 2022;17(1):15-21.

Lenacapavir as part of a combination regimen in treatment-naïve PWH [people with HIV]: week 54 results.

Gupta SK, Sims J, Brinson C, et al. Presented at: Conference on Retroviruses and Opportunistic Infection. February 12-16, 2022. Abstract 138.

Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic.

Howe ZW, Norman S, Lueken AF, et al. Pharmacotherapy. 2021;41(8):686-699.

Experiences with long acting injectable ART: a qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.

Kerrigan D, Mantsios A, Gorgolas M, et al. PLoS One. 2018;13(1):e0190487.

Efficacy and freedom: patient experiences with the transition from daily oral to long-acting injectable antiretroviral therapy to treat HIV in the context of phase 3 trials.

Mantsios A, Murray M, Karver TS, et al. AIDS Behav. 2020;24(12):3473-3481.

Long-acting lenacapavir in people with multidrug resistant HIV-1: week 52 results.

Ogbuagu O, Segal-Maurer S, Brinson C, et al. Presented at: Conference on Retroviruses and Opportunistic Infections; February 12-16, 2022; virtual conference. Abstract 491.

Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.

Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

Overton ET, Richmond G, Rizzardini G, et al. Lancet. 2021;396(10267):1994-2005.

The promise of improved adherence with long-acting antiretroviral therapy: what are the data?

Scarsi KK, Swindells S. J Int Assoc Provid AIDS Care. 2021;20:23259582211009011.

Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection.

Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. N Engl J Med. 2022;386(19):1793-1803.

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.

Linked Resources

Clinical Practice Guidelines

Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.

US Department of Health and Human Services

Patient and Caregiver Resources

AIDSMap resources.

NAM Publications

Resources for persons living with HIV.

Centers for Disease Control and Prevention

HIV resources.

National Institutes of Health

Related activities

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

Faculty: José R. Arribas, MD; Onyema Ogbuagu, MBBCh, FACP, FIDSA
Release: 07/26/2022
Expiration: 07/26/2023